Skip to main content
Metallomix

  • Engineering new medicines at the atomic level

    Metallomix is developing novel therapies based on its proprietary isotope-selective modulation of metal-dependent biology, beginning with enriched stable zinc isotopes

Clinical Stage

Lead Oncology Program

64Zn

Current Isotope Focus

Versatile ISM Platform

Drug Development Platform

THE PLATFORM

From science to drug candidates

Our Isotope-Selective Modulation platform integrates isotope chemistry, disease biology and translational pharmacology to develop stable-isotope-enriched drug candidates with defined therapeutic plans

Map Target Disease Biology

Prioritize metal-dependent pathways and disease settings where altered metal handling or isotope disfractionation can be measured and mechanistically interrogated

Read More

Design Isotope-Selective Compounds

Develop enriched stable-isotope formulations and molecules, then characterize chemistry, exposure, biological activity, safety and efficacy

Read More

Translate with Biomarkers

Link mechanistic hypotheses to pharmacodynamic and disease biomarkers to support clinical development and indication selection

Read More

THE LEAD PROGRAM

KLS-1 / Isotozin

An investigational, clinical stage isotope-enriched zinc metallodrug candidate being developed first in oncology, with additional research programs exploring metabolic and neurological applications

KLS-1 is designed to test how isotope-selective modulation of zinc-dependent biology can alter disease-relevant cellular processes

Read More

Modality

Enriched stable isotope zinc-64

Lead Setting

Oncology: Solid tumors

No Radiation

Non-radioactive isotope

Present Stage

Phase 1 recruiting patients

THE COMPANY

Max Temnik, PhD (The Founder)

We are out-of-the box thinkers charged with the mission to bring forward truly novel medicines through understanding isotopic fractionation in human cells and tissues, and by developing safe and effective isotope selective modulators targeting scientifically validated pathways. 

Our research is focused on the roles metals and isotopic fractions play in human physiology, with current attention to inflammation and oxidative stress. By selectively modulating cellular processes with non-radioactive isotopes, we aim to restore the healthy interplay between cellular homeostasis and inflammatory and oxidative response, and to offer new, safer and more effective treatments for oncological and age-related diseases.